Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis.
Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis.
复制标题
经导管动脉化疗栓塞加索拉非尼与单独经导管动脉化疗栓塞治疗晚期肝细胞癌的荟萃分析
DOI：
10.1186/s12885-017-3707-5
复制
发表时间：
2017-11-06
期刊：
影响因子：
3.8
通讯作者：
Ma H
中科院分区：
文献类型：
--
作者：
Cai R;Song R;Pang P;Yan Y;Liao Y;Zhou C;Wang S;Zhou X;Wang H;Zhang H;Sun H;Ma H
研究背景索拉非尼联合经导管肝动脉化疗栓塞术(TACE)治疗晚期肝细胞癌的研究较多，但结果存在争议。方法应用计算机检索PubMed、Web of Science、Cochrane图书馆、中国国家知识基础设施、万方和中国科技期刊数据库2009-01/2016-06的相关文献。最终分析包括14项研究和1670名患者。结果综合治疗组总生存率(RR=1.6 2，95%可信区间=11.34~1.94，P<； 0.00001)、客观有效率(RR=1.43，95%CI=11.26~1.62，P<)、疾病控制率(RR=1.26~1.62，P<)均明显优于单纯TACE组。 0.00001)、0.5年期操作系统(OR=2.60，95%CI=11.57-4.29，p= 0.0002)和1年期操作系统(OR=1.8895%CI=1.39-2.53，p<； 0.0001)。与单纯TACE治疗相比，联合治疗的不良事件发生率较高，最常见的不良事件为乏力、手足皮肤反应和腹泻，均可耐受。结论Meta分析表明联合治疗是安全有效的。
BackgroundMany studies have combined sorafenib with transcatheter arterial chemoembolization (TACE) to treat patients with advanced hepatocellular carcinoma (HCC), but the results are disputable. Thus, we conducted this meta-analysis to assess the efficacy and safety of the combination treatment in patients with advanced HCC.MethodsClinical data were collected from a computer search of literature published from January 2009 to June 2016 in PubMed, Web of Science, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wan Fang and the China Science and Technology Journal Database (CSTJ). The final analysis included 14 studies and 1670 patients. The primary endpoints were overall survival (OS), the objective response rate (ORR) and the disease control rate (DCR).ResultsThe combination group exhibited significantly more improvement than the group treated with TACE alone in ORR (RR =1.62, 95% confidence interval (CI) = 1.34–1.94,p< 0.00001), DCR (RR = 1.43, 95% CI = 1.26–1.62,p< 0.00001), 0.5-year OS (OR = 2.60, 95% CI = 1.57–4.29,p= 0.0002) and 1-year OS (OR = 1.88, 95% CI =1.39–2.53,p< 0.0001). The incidence of adverse events from combination therapy was increased compared to that from treatment with TACE alone, and the most commonly reported adverse events were fatigue, hand-foot skin reaction and diarrhoea, which were bearable.ConclusionsThe meta-analysis indicated that combination therapy is safe and efficient for clinical application.
登录
查看更多内容
影响因子：
25.7
作者：
Lencioni, Riccardo;Llovet, Josep M.;Bruix, Jordi
通讯作者：
Bruix, Jordi
影响因子：
3
作者：
Erhardt, Andreas;Kolligs, Frank;Haussinger, Dieter
通讯作者：
Haussinger, Dieter
影响因子：
3.8
作者：
Hoffmann, K.;Glimm, H.;Radeleff, B.;Richter, G.;Heining, C.;Schenkel, I.;Zahlten-Hinguranage, A.;Schirrmacher, P.;Schmidt, J.;Buechler, M. W.;Jaeger, D.;von Kalle, C.;Schemmer, P.
通讯作者：
Schemmer, P.
影响因子：
9
作者：
Huang, Jiwei;Yan, Lvnan;Zeng, Yong
通讯作者：
Zeng, Yong
影响因子：
--
作者：
Berk, Veli;Kaplan, Mehmet Ali;Gumus, Mahmut
通讯作者：
Gumus, Mahmut